Please note that following on from information provided to NICE by the company in April 2012, the appraisal of Vorinostat in combination with bortezomib for the treatment of multiple myeloma in people who have received at least one prior therapy [ID501] was suspended from NICE’s work programme. As no further information has been received from the company the topic has been discontinued.
| Status | Discontinued |
| Technology type | Medicine |
| Decision | Selected |
| Process | TA |
| ID number | 501 |
| Referral date | 01 November 2011 |
| Topic area |
|
Provisional Schedule
| Closing date for invited submissions / evidence submission: | TBC |
| 1st appraisal committee meeting: | TBC |
Project Team
| Communications manager: | TBC |
| Executive Lead: | TBC |
| Project manager: | Lori Farrar |
| Technical Lead: | TBC |
Email enquiries
- If you have any queries please email scheduling@nice.org.uk
Timeline
Key events during the development of the guidance:
| Date | Update |
|---|---|
| 23 January 2023 | Discontinued. Please note that following on from information provided to NICE by the company in April 2012, the appraisal of Vorinostat in combination with bortezomib for the treatment of multiple myeloma in people who have received at least one prior therapy [ID501] was suspended from NICE’s work programme. As no further information has been received from the company the topic has been discontinued. |
| 9 May |
The Institute has now been informed by the manufacturer that it will no longer be pursuing a licensing application for vorinostat in this indication, therefore, NICE has decided to suspend this appraisal on its current work programme for the time being. As this topic has been referred to the Institute we will continue to monitor any development and will update interested parties if the situation changes. |
For further information on our processes and methods, please see our CHTE processes and methods manual